Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 26;20(1):20241134.
doi: 10.1515/med-2024-1134. eCollection 2025.

The safety and efficacy of BCG combined with mitomycin C compared with BCG monotherapy in patients with non-muscle-invasive bladder cancer: A systematic review and meta-analysis

Jianping Liu  1 , Weijian Zhou  2 , Wei Zhang  1 , Congwang Chang  1 , Peng Zhang  1 , Guanghua Fu  1
Affiliations
Review

The safety and efficacy of BCG combined with mitomycin C compared with BCG monotherapy in patients with non-muscle-invasive bladder cancer: A systematic review and meta-analysis

Jianping Liu et al. Open Med (Wars). .

Abstract

Introduction: We sought to determine the efficacy and safety of Bacillus Calmette-Guérin (BCG) combined with mitomycin C (MMC) compared with BCG monotherapy in intravesical therapies for non-muscle-invasive bladder cancer (NMIBC).

Methods: We followed the recommended PRISMA guidelines for systematic reviews. Systematic literatures were performed on PubMed, EMBASE, Cochrane Library, CNKI, CBM, VIP, Wan Fang, and Clinical Trials.gov. Randomized controlled trials (RCTs) comparing BCG combined with MMC and BCG monotherapy in intravesical therapies for non-muscle-invasive bladder cancer patients were searched until August 1, 2023.

Results: This meta-analysis included 11 RCTs with a total of 1,349 subjects. Compared with BCG monotherapy, BCG combined with MMC was associated with lower disease recurrence rate (relative risk [RR] 0.66, 95% confidence interval [CI]: 0.56-0.77, P < 0.00001), disease progression rate (RR 0.61, 95% CI: 0.44-0.84, P = 0.003), and disease-specific mortality (RR 0.46, 95% CI: 0.26-0.78, P = 0.004). However, there was a higher incidence of systemic adverse reactions (RR 1.57, 95% CI: 1.22-2.02, P = 0.0004). There was no significant difference in the incidence of local adverse reactions (RR 1.07, 95% CI: 0.95-1.20, P = 0.26) and all-cause mortality (RR 0.80, 95% CI: 0.62-1.03, P = 0.08) between the two groups.

Conclusions: BCG combined with MMC was associated with a decreased risk of bladder cancer recurrence and disease progression compared with BCG monotherapy. However, there was no significant difference in the incidence of local adverse events and all-cause mortality between the two groups. Due to the limitations of the number and quality of the included studies, more high-quality RCTs are needed to further explore the efficacy and safety of combined therapies.

Keywords: Bacillus Calmette-Guérin; intravesical therapies; mitomycin C; non-muscle-invasive bladder cancer; urinary bladder neoplasms.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flow diagram of studies’ selection process.
Figure 2
Figure 2
Assessment of risk of bias.
Figure 3
Figure 3
Forest plot of primary outcomes: (a) recurrence rate and (b) progression rate.
Figure 4
Figure 4
Forest plot of Secondary outcomes: (a) local adverse reactions; (b) systemic adverse reactions; (c) disease-specific mortality; and (d) all-cause mortality.
Figure 5
Figure 5
Forest plot and meta-analysis of recurrence rate between BCG combined with MMC and BCG alone: subgroup analysis based on induced perfusion and maintenance perfusion.
Figure 6
Figure 6
Publication bias: Funnel plot and Begg’s test and Egger’s test of the eleven studies involving the outcomes of recurrence rate.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71(3):209–49. 10.3322/caac.21660. - DOI - PubMed
    1. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4–34. 10.1016/j.urology.2005.07.062. - DOI - PubMed
    1. Sylvester RJ, Rodriguez O, Hernandez V, Turturica D, Bauerova L, Bruins HM, et al. European association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: An update from the EAU NMIBC guidelines panel. Eur Urol. 2021;79(4):480–8. 10.1016/j.eururo.2020.12.033. - DOI - PubMed
    1. Babjuk M, Burger M, Capoun O, Cohen D, Comperat EM, Dominguez Escrig JL, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75–94. 10.1016/j.eururo.2021.08.010. - DOI - PubMed
    1. Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: Which patients benefit from the instillation? Eur Urol. 2016;69(2):231–44. 10.1016/j.eururo.2015.05.050. - DOI - PubMed

LinkOut - more resources